PSPablo Jose Sanchez

Pablo Jose Sanchez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Jose Sanchez has a total of 481 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management of neonates born to mothers with reactive serologic tests for syphilis

    by Abigail Z. Nishikawa, W. Christopher Golden, Alexa J. Brumfiel, Sameer B. Chand, Pablo J. Sánchez

    Purpose of review: The dramatic resurgence of maternal and congenital syphilis in the United States highlights the need for their optimal management as syphilis in pregnancy can result in substantial neonatal morbidity and mortality. This review summarizes current epidemiology and discusses guidance on the management of neonates born to mothers with reactive serologic tests for syphilis. Recent findings: Timely communication with local health department professionals is essential for optimal management of mothers with reactive serologic tests for syphilis and their neonates. Knowledge of maternal syphilis treatment history by partnering with local jurisdictions can circumvent much of the incertitude surrounding neonatal management. All neonates born to mothers with reactive serologic tests for syphilis should be tested using a nontreponemal (‘lipoidal antigen’) test. However, a reactive test may only indicate maternal nontreponemal IgG antibodies that are transferred transplacentally to the fetus. Therefore, neonatal management depends on maternal history and treatment for syphilis as well as clinical, laboratory, and radiographic findings in the neonatal evaluation. Existing management algorithms are complex, highlighting the need for a more practical, yet safe, approach. Summary: A neonatal management guideline is proposed that may simplify the management of neonates born to mothers with reactive serologic tests for syphilis while advocating for expanded use of single-dose benzathine penicillin G therapy.

  • Open Access

    Sepsis precoz en recién nacidos: recomendaciones de la Rama de Neonatología, Sociedad Chilena de Pediatría

    by Soledad Urzúa, Alberto Toso, Liliana Leguizamon, Regina Perez, Francisca Jung, Paulina Toso, Jose Novoa, Pablo Sánchez

    La sepsis precoz constituye una de las principales causas de morbimortalidad en el periodo neonatal. La epidemiología y etiología han cambiado en los últimos años, influido en gran parte por la profilaxis contra Streptococcus agalactiae o Streptococcus grupo B y la emergencia de Escherichia coli como el principal agente en recién nacidos (RN) pretérmino. Desde hace varios años, se ha incorporado a la práctica clínica el Calculador de Riesgo de Sepsis Precoz, herramienta que permiten un acercamiento más estandarizado, con menores tasas de hospitalización y disminución del uso de antibióticos. Además, el uso de nuevas técnicas de laboratorio y la mejoría en la sensibilidad de los cultivos, contribuyen a un mejor diagnóstico y por ende, un tratamiento óptimo y acotado. Este artículo es una recomendación de la Rama de Neonatología de la Sociedad Chilena de Pediatría y tiene como objetivo revisar los aspectos epidemiológicos, etiológicos y factores de riesgo para sepsis precoz, incluyendo las recomendaciones de la Academia Americana de Pediatría y el Colegio Americano de Obstetricia y Ginecología publicadas en el año 2019. Se analizan las principales manifestaciones clínicas, herramientas diagnósticas y tratamiento. Considerando los elementos antes descritos y las publicaciones de los últimos años, se incorporan recomendaciones para el enfrentamiento de los recién nacidos con sospecha de sepsis precoz.

  • Open Access

    Neonatal bacterial meningitis: the elusive search for markers of severity

    by Pablo J. Sánchez, Antoniece S. Duncanson, Jackson T. Gamer, Darrah N. Haffner

  • Open Access

    Urinary tract infection in the neonatal intensive care unit

    by Jacqueline Magers, Alexandra Burton, Pavel Prusakov, Natalie O. White, Randy R. Miller, Richard Moraille, Anthony R. Theile, Pablo J. Sánchez, Jacqueline K. Magers, Joshua R. Watson, et al.

    Objective: To determine adherence and safety of a diagnostic (culture, urinalysis) and therapeutic (5-day antibiotic course with a time-out) guideline for urinary tract infection (UTI) in the Neonatal Intensive Care Unit Study design: Prospective surveillance of non-bacteremic UTIs from 11/2020-12/2022. Safety outcomes were defined by re-initiation of antibiotics within 7 days for a subsequent UTI due to the same organism and overall and UTI-related mortality. Results: 77 infants received treatment for 93 UTIs with 77% (72/93) adherence to diagnostic criteria; 90% (82/91) of infants received ≤6 days of definitive treatment (median [IQR] antibiotic duration 5 [5–6] days). Antibiotics were restarted within 7 days for a recurrent (same organism) UTI in 1/91 (1%) UTIs. Mortality was 4% (4/93); none were due to UTI. Conclusion: Adherence to diagnostic UTI criteria was 77%. 90% of infants received short course treatment that was associated with a 1% failure rate. No safety concern was identified.

  • Pitfalls in the Serologic Diagnosis of Maternal Syphilis: A Case Series

    by Sameer B. Chand, Traci Pifer, Sebastian Martinez, Charles Miller, Regent Epperson, Bianca Jones, Tanisha Pettus, Pablo J. Sánchez

    Pregnancy is associated with false-positive treponemal and nontreponemal screening test results. We present 5 pregnant women who had reactive treponemal screening and nontreponemal test results but nonreactive Treponema pallidum– particle agglutination test result. Reliance on treponemal screening tests may result in misdiagnosis and unnecessary treatment, unless a specific treponemal test is performed.


  • Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study

    by Edward P Acosta, Inmaculada Aban, Kevin J Ryan, Pablo J Sánchez, Carina A Rodriguez, José R Romero, Sunil K Sood, Nazha Abughali, Ravit Arav-Boger, Roberta L DeBiasi, et al.

    Background: Ganciclovir remains the primary therapeutic for cytomegalovirus (CMV) infections in early infancy, but its pharmacokinetics and dosing in very preterm infants with end-organ CMV disease have not been fully evaluated. Methods: Premature infants with confirmed CMV infection and receiving ganciclovir as standard of care were enrolled into a pharmacokinetic (PK) sampling study. All infants were 500 g at enrollment. Plasma for ganciclovir quantitation was collected at steady state at 0, 1, 2–3, 5–7, and 10–12 hours after the dose. Specimens were shipped and analyzed, and PK parameters were calculated in real time. Noncompartmental and modeling approaches were used for analysis. Results: Eighteen infants were enrolled; their mean gestational age at delivery was 26.7 weeks, and their mean age and weight at enrollment were 42 days and 1519.0 g, respectively. PK assessments were completed in 17. The geometric mean dose and resulting 12-hour area under the curve were 5.19 mg/kg and 52.7 mg · h/L, respectively. A total of 85 ganciclovir concentration-time data points were available for modeling. A 1-compartment power covariate model with weight and serum creatinine on clearance and weight on distribution volume was used. Noncompartmental and modeled PK parameters were similar. Conclusions: These are the first intravenous ganciclovir population PK data with covariate assessments in premature infants being treated for CMV disease. Results suggest an intravenous dose of 5 mg/kg every 12 hours may be an appropriate starting regimen in of premature infants with congenital CMV. Additional data are needed in this and other populations to better define optimal ganciclovir exposure targets.


  • Role of Viral Codetections in Young Children With Respiratory Syncytial Virus Infection

    by Cristina Garcia-Mauriño, Helena Brenes-Chacon, Cristina Tomatis-Souverbielle, Pablo J Sanchez, Octavio Ramilo, Asuncion Mejias

  • Management of neonates born to mothers with active genital herpes simplex virus infection: an alternative approach

    by Pablo J. Sánchez, Natalie O. White, Rachel J. Graf, Jeanette Taveras

    Purpose of review: Although considered a rare disease, neonatal HSV infection represents a disease in urgent need of preventive strategies, as it results in substantial neonatal morbidity and mortality. This review summarizes its current epidemiology and discusses guidances on the management of the asymptomatic neonate born to mothers with active genital HSV infection. Recent findings: Timely detection and early high-dose acyclovir treatment of neonatal HSV infection decreases mortality. All neonates born to mothers with active genital HSV infection in the third trimester or at delivery should be tested for HSV infection. The newborn management has depended on whether the mother has experienced a primary or recurrent genital HSV infection based on maternal serologic testing and PCR testing of the genital lesion. An alternative strategy on neonatal management is proposed that is based on type of maternal HSV infection and perinatal risk factors. Summary: The incidence of neonatal HSV infection is increasing with more infections due to HSV-1 than HSV-2. Guidances addressing management of the asymptomatic newborn exposed to active maternal genital HSV infection are discussed.


  • The Case for Universal Newborn Congenital Cytomegalovirus Screening

    by Sarah M. Sánchez, Margaret Kettler, Rakhi Gupta Basuray, Prashant S. Malhotra, Pablo J. Sánchez


  • Open Access

    SARS-CoV-2 induced immune perturbations in infants vary with disease severity and differ from adults’ responses

    by Djamel Nehar-Belaid, Asunción Mejías, Zhaohui Xu, Radu Marches, Rushil Yerrabelli, Guo Chen, Sara Mertz, Fang Ye, Pablo J. Sánchez, John S. Tsang, et al.

    Differences in immune profiles of children and adults with COVID-19 have been previously described. However, no systematic studies have been reported from infants hospitalized with severe disease. We applied a multidimensional approach to decipher the immune responses of SARS-CoV-2 infected infants (n = 26; 10 subacute, 11 moderate and 5 severe disease; median age = 1.6 months) and matched controls (n = 14; median age = 2 months). Single cell (scRNA-seq) profiling of PBMCs revealed substantial alterations in cell composition in SARS-CoV-2 infected infants; with most cell-types switching to an interferon-stimulated gene (ISGhi) state including: (i) CD14+ monocytes co-expressing ISGs and inflammasome-related molecules, (ii) ISGhi naive CD4+ T cells, (iii) ISGhi proliferating cytotoxic CD8+ T cells, and (iv) ISGhi naive and transitional B cells. We observe increased serum concentrations of both interferons and inflammatory cytokines in infected infants. Antibody responses to SARS-CoV-2 are also consistently detected in the absence of anti-IFN autoantibodies. Compared with infected adults, infants display a similar ISG signature in monocytes but a markedly enhanced ISG signature in T and B cells. These findings provide insights into the distinct immune responses to SARS-CoV-2 in the first year of life and underscore the importance of further defining the unique features of early life immunity.